Effects of Dietary Supplementation of Arginine-Silicate- Inositol and Phytase Complex on Performance and Blood Biochemical Traits of Laying Hens.

Arginine silicate inositol complex (ASI; Arg = 49.47%, silicone = 8.2%, inositol = 25%) is a novel, bioavailable source of Si and Arg and may offer potential benefits for laying hens' performance. The aim of this study was to evaluate the effect of Arginine-Silicate and inositol/phytase on the performance of laying hens. A total of 90 laying hens, 25 weeks old, were randomly assigned to 6 treatments with 3 replicates (5 birds per replicate). The treatments were as follows: 1ST treatment PC: positive Control group (basal diet without additives (, 2nd treatment: basal diet +1000 mg/kg arginine-silicate complex (49.5±8.2 % respectively), 3d treatment: basal diet +1000 mg/kg arginine-silicate- inositol (ASI) complex (49.5, 8.2 , 25 % respectively) , 4th treatment: T 2 +500 FTU/kg , 5th treatment: T2 +1000 FTU/kg and 6th treatment: T2+2000 FTU/kg . Results indicate a significant increase (P<0.05) in hen house production (H.H. pro.%) of T5 (95.06 %)compared with T1(91.67%) and no significant differences between T2, T3, T4, T6 (91.84, 93.21, 93.46, 92.98%) and compared with T1 and T5. were no significant difference observed in average egg weight and egg mass between the experimental treatments all over the period. Daily feed intake (DFI) significantly decreased (P<0.05) with supplementing diets with deferent levels of phytase with arginine-silicate mixture T4, T5, andT6 (113.56،113.06، 112.10 g) compared with T1 (114.34 g ) which has no significant differences compared with T2 and T3 (113.96, 113.92 g). Phytase supplementation significantly (P<0.05) improved FCR g feed/egg in T5 (119.02) compared with T1 and T2 (124.89, 124.32), while no significant differences between T3.T4.T6 treatments (122.39, 121.80, 120.69) respectively and compared with other treatments. The experimental treatments observed no significant difference in g feed/ g egg.

Effects of Dietary Supplementation of arginine-silicate- Inositol and Phytase Complex on Egg Quality, Egg Shell Strength, and Blood Biochemical Characteristics of Laying Hens.

This study aimed to determine the effects of Arginine silicate inositol complex (ASI; Arg=49.47 %, silicone=8.2 %, inositol=25%) supplementation on egg quality, shell strength, and blood biochemical traits of laying hens, as well as the effects of substituting inositol with varying concentrations of phytase on the traits as mentioned above. 90 Lohmann Brown laying hens, 26 weeks old, were randomly distributed in 6 treatments with 3 replicates (cage) and 5 birds per replicate. The isocaloric and isonitrogenic diets are used according to the age period requirements of the Lohmann Brown Classic management guideline. The treatments were as follows: 1ST treatment T1: received basal diet without additives, T2 received basal diet +1000 mg/kg arginine-silicate mixture (49.5±8.2 % respectively), T3 received basal diet +1000 mg/kg arginine-silicate- inositol (ASI) mixture (49.5, 8.2 , 25 % respectively), T4 received basal diet +1000 mg/kg arginine-silicate mixture (49.5±8.2% respectively) +500 FTU/kg, T5 received basal diet +1000 mg/kg arginine-silicate mixture (49.5±8.2% respectively) +1000 FTU/kg and T6 received basal diet +1000 mg/kg arginine-silicate mixture (49.5±8.2% respectively) +1000 FTU/kg +2000 FTU/kg. Results indicate a significant increase (P<0.05) in the relative yolk weight in T4, T5, and T6 (26.93, 26.83, 26.77%) compared to T1 (25.84%) and a significant increase (P≤ 0.05) in T4, T5 compared to T3 (26.02%), while no differences observed between T2 (26.17%) compared to other experimental treatments. The relative albumin weight significantly decreased (P≤0.05) in phytase supplementation treatments T4, T5, and T6 (63.21, 63.05, 63.22%) compared to T1, T2, T3 (64.99, 64.30, 64.08%), while a significant decrease (P≤0.05) observed in T3 compared to T1. The relative shell weight significantly increased (P≤0.05) in T3, T4, T5, and T6 (9.90, 9.86, 10.12, 10.02%), respectively, compared to T1, T2 (9.17, 9.53%) with a significant increase (P≤0.05) in relative shell weight in T2 compared to T1. The eggshell thickness significantly increased (P≤0.05) in T3, T4, T5, T6 treatments (0.409, 0.408, 0.411, 0.413 mm), respectively compared to T1, T2 (0.384, 0.391 mm). A significant increased (P≤0.05) was observed in eggshell thickness in T2 compared to T1. A significant increase (P≤0.05) was observed in the egg shell breaking strength in T3 and T5 treatments (59.40, 58.83) compared to T1 and T2 (46.20, 48.23). No significant differences were observed between T4 and T6 (53.90, 53.57) compared to other experimental treatments. Non HDL, calcium, and phosphorus levels in blood serum significantly increased (P≤0.05) in T3, T4, T5, and T6 treatments compared to T1 and T2 treatments.

Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.

OBJECTIVE: To evaluate the association between the intensity and duration of glaucoma topical therapy and severity of signs and symptoms of ocular surface disease (OSD). DESIGN: Single-site, prospective, controlled, cross-sectional study. PARTICIPANTS: Sixty-one patients with no diagnosis of or previous treatment for OSD were identified. METHODS: Patients were assigned to 2 groups: the glaucoma group with 31 patients diagnosed with primary open-angle glaucoma and using at least 1 topical intraocular pressure (IOP)-lowering medication and the control group including 30 patients with no diagnosis of glaucoma or history of topical therapy usage. The right eye of each patient was arbitrarily chosen. Each patient completed an Ocular Surface Disease Index (OSDI) questionnaire and underwent evaluation of the ocular surface by conjunctival and corneal lissamine green (LG) staining and tear breakup time (TBUT). The intensity index (drops/wk × therapy duration in years) was calculated to quantify the topical therapy. RESULTS: OSDI scores of the glaucoma group correlated to the intensity index (r = 0.46, CI 0.13-0.69). The glaucoma group had a higher mean OSDI score than the control group (18.97 ± 9.5 versus 6.25 ± 5.7, p = 5.85E-08). Abnormal TBUT and LG staining scores were prevalent in the glaucoma group compared with the control group (68% vs 17%, p = 0.000078; 65% vs 3%, p = 2.9E-07). CONCLUSIONS: Patients on glaucoma therapy have a greater prevalence of OSD symptoms, and their intensity index correlates to the OSDI score. The intensity index reflects quantitatively the amount of treatment and can be further validated in future studies as a predicting tool for OSD development.

Association of hypothyroidism in patients with migraine and tension-type headache disorders in Kashmir, North India

Objective: This case control study was undertaken to ascertain the frequency of subclinical and overt hypothyroidism in patients with various types of primary headache disorders in Kashmir, North India. Methods: The study was conducted in a tertiary care (university of Kashmir) hospital of North India. The study subjects consisted of 250 patients with primary headache disorders. This was compared with an age-sex matched control of 500 subjects. Thyroid function tests were performed by new automated immunochemiluminometric assay. Results: Among patients with primary headache disorders, subclinical hypothyroidism was present in 22% and overt hypothyroidism in 7.2%. On the other hand, subclinical hypothyroidism was observed in 11.2% and overt hypothyroidism in 1.2% of cases in the control group, the differences between primary headache and control group was statistically significant (p 0.05). Conclusion: Hypothyroidism is found to be a co-morbidity or predisposes to the development of chronic headache (tension-type headache and migraine) in this North Indian study.

Long term efficacy of repeat selective laser trabeculoplasty.

PURPOSE: To evaluate long term intraocular pressure (IOP) control after repeat selective laser trabeculoplasty (SLT). METHODS: This single center study retrospectively reviews the electronic medical records of patients with open angle glaucoma undergoing repeat SLT. Eyes with prior argon laser trabeculoplasty, or incisional surgery before or during the study period were excluded. Demographics, laser parameters, number of glaucoma medications and IOP at baseline and after 1, 4, 8, 12, 18 and 24 months were collected. The percentage of subjects with IOP reduction >20% and ≥15% from baseline was determined. RESULTS: A total of 45 eyes of 25 subjects with mean age of 73 ± 9 years undergoing repeat SLT were included. Repeat SLT was performed at a mean interval of 28.3 ± 12.7 months after initial treatment. Mean IOP reductions were statistically significant with repeat SLT as compared to baseline at 1, 4, 8, 12, 18 and 24 months' follow-up. Change in IOP after first and repeat SLT were comparable at most time points except at 4, 8 and 12 months when initial treatment had yielded significantly greater reductions. At 24 months, 29% and 39% of eyes achieved IOP reduction >20% and ≥15% respectively after repeat SLT as compared to 36% and 54% of eyes following initial treatment (P > 0.05). CONCLUSION: Repeat SLT is effective in lowering IOP up to 24 months. Long term IOP control was achieved in 29-39% of eyes following repeat treatment in this cohort of patients.

Technique for intraoperative reuse of Ex-PRESS delivery system.

PURPOSE: To report a new technique for reloading the Ex-PRESS glaucoma filtration device on the Ex-PRESS delivery system (Alcon Laboratories) for revised placement of an implant. PATIENT AND METHODS: The Ex-PRESS is provided on a single-use delivery system. A patient who underwent Ex-PRESS placement was noted intraoperatively to have had an unsatisfactory implant position upon initial insertion. The used inserter metallic rod was manipulated to resume its original shape. The implant was removed and reloaded onto the delivery system, which was then used to place it in the desired position. RESULTS: Intraoperative delivery system reloading is possible and facilitates repositioning of the Ex-PRESS implant. CONCLUSIONS: This technique for reloading the Ex-PRESS will allow the surgeon to make adjustments to an unsatisfactorily positioned implant upon initial insertion. This may help optimize implant positioning, minimize insertion malpositioning, and reduce the cost and time of using more than 1 device.

Radon emanation from radium specific adsorbents.

Pilot studies were undertaken to quantify the total activity of radon that is eluted following no-flow periods from several Ra-226 adsorbents loaded to near exhaustion. The adsorbents studied included two types of barium sulphate impregnated alumina (ABA-8000 and F-1) and Dowex MSC-1 resin treated by either barium hydroxide or barium chloride. In parallel, radium loaded plain activated aluminas and Dowex MSC-1 resin were similarly investigated. The results revealed that radon was quantitatively eluted during the first few bed volumes of column operation after no-flow periods. Although similar radon elution profiles were obtained, the position of the radon peak was found to vary and depended on the adsorbent type. Radon levels up to 24 and 14 kBq dm(-3) were measured after a rest period of 72h from radium exhausted Dowex MSC-1 treated with barium chloride and F-1 impregnated alumina with barium sulphate, respectively. The eluted radon values measured experimentally were compared to those calculated theoretically from accumulated radium quantities for the different media. For plain adsorbents, an agreement better than 10% was obtained. For treated resin-types a consistency within 30% but for impregnated alumina-types high discrepancy between respective values were obtained.

[Myositis ossificans circumscripta: the contribution of imaging]. / La myosite ossifiante circonscrite: apport de l'imagerie.

OBJECTIVES: Illustrate the specific and nonspecific aspects of myositis ossificans circumscripta (MOC) in standard imaging, cross-sectional imaging (sonography, CT, and MRI), and bone scintigraphy. PATIENTS AND METHODS: Eight patients presenting with MOC (three men and five women) were explored using standard radiography (eight cases), sonography (seven cases), scintigraphy (four cases), CT (six cases), and MRI (four cases). RESULTS: Standard x-rays and sonography of the soft tissue showed a well-defined mass containing calcifications in 75% of the cases. The CT scan diagnosed MOC in four cases, showing calcified masses separated from the adjacent bone by a clear radiotransparent border or afferent peripheral tumoral calcifications highly suggestive of MOC. MRI was nonspecific. Bone scintigraphy showed hyperfixation in the four cases imaged. CONCLUSION: Standard x-rays were useful to demonstrate the calcifications of MOC and to identify their relation with the subjacent bone. Sonography and bone scintigraphy were interesting in monitoring the lesion's maturation. In addition to early detection of calcifications, CT can precisely localize the lesion before surgical ablation. MRI is a very sensitive technique in detecting small lesions at an early stage, but it is nonspecific and does not remove the necessity of biopsy to eliminate the possibility of a malignant disease.

Nanoscale anionic macromolecules for selective retention of low-density lipoproteins.

Synthetically designed anionic nanocarriers that mimic the charge properties of glycosaminoglycans can potentially sequester low-density lipoproteins (LDL) during the treatment of atherosclerosis. In this study, we explore the LDL retentivity of 15-20 nm anionic micelles formed from amphiphilic scorpion-like macromolecules (AScMs) as building blocks. The macromolecules comprise four aliphatic chains attached to mucic acid and a linear polyethylene glycol (PEG) segment to form micellar nanocarriers with a hydrophobic core and hydrophilic corona. Dynamic light scattering and transmission electron microscopy studies indicate that the carboxylate-terminated nanocarriers (20 nm) sequester LDL (22 nm), resulting in complexes with a diameter of 60-90 nm, but neutral ethoxy-terminated nanocarriers do not retain LDL. Further, carboxylate-terminated nanocarriers consistently bound to unoxidized LDL (Relative Electrophoretic Mobility, REM=1.0) and mildly oxidized LDL (REM=1.5), but not highly oxidized LDL (REM=3.6), whereas the neutral nanocarriers displayed no preference/affinity at all, indicating that the nanocarrier-LDL binding is charge-dependent. The binding affinity of unoxidized LDL for differentially charged nanocarriers, formed from varying ratios of carboxylate- and ethoxy-terminated macromolecules, was quantified. The 100% carboxylated nanocarriers elicited the highest binding affinity (K(d)=567 nm), whereas mixed micelles elicited significantly lower levels of binding affinity. Our results highlight the promise of synthetically designed nanomaterials in lipoprotein retention, a key step in managing the escalation of atherosclerosis.